Objective: The disease association of the common 1858C>T Arg620Trp (rs2476601) nonsynonymous single nucleotide polymorphism (SNP) of protein tyrosine phosphatase; nonreceptor type 22 (PTPN22) on chromosome 1p13 has been confirmed in type 1 diabetes, and also in other autoimmune diseases including rheumatoid arthritis and Graves' disease. Some studies have reported additional associated SNPs independent of rs2476601/Trp 620 , suggesting that it may not be the sole causal variant in the region; and that the relative risk of rs2476601/Trp 620 is greater in lower risk by HLA class II genotypes than in the highest risk class II risk cateogory.
o date there are ten loci with confirmed evidence for association with type 1 diabetes: the MHC HLA class I and II genes (1; 2), INS (3; 4), the CTLA4 locus (5; 6), PTPN22 (7), IL2RA (8; 9; 10 ), IFIH1 (11) and the regions on chromosomes12q24, 12q13, 16p13 and 18p11 (12) (13) (14) . With the recent capability to scan hundreds of thousands of SNPs across the genome in thousands of samples, the identification of complex disease genes and regions has greatly been enhanced (12). However, the localisation of the causal variant(s) in the chromosome regions identified by genome-wide association (GWA) studies requires comprehensive resequencing, extensive genotyping and statistical analysis in large sample sets. With the exceptions of MHC(2), CTLA4-ICOS (6), IL2RA (8) and INS (4), which have been subjected to further resequencing and genotyping to try to narrow down candidates for the causal variant(s), the other type 1 diabetes loci have not yet been studied in any great detail (6; 11; 13) . For PTPN22, there has been extensive focus on the single nsSNP rs2476601/Arg620Trp (7; 15-18) . Functional studies suggest that the Trp 620 allele has gain-of-function, immunosuppressive effects compared to the more common allele Arg 620 (19) (20) (21) . However, there have been attempts to assess if there are other variants that confer risk of disease that are independent of rs2476601/Trp 620 (22; 23). One of the largest studies so far to characterise disease association with PTPN22, resequenced the coding regions of the gene in 48 North American individuals and genotyped 37 SNPs in or near PTPN22 in up to 1,136 rheumatoid arthritis (RA) cases and 1,797 controls (475 cases and 475 controls = set 1; 661 cases and 1,322 controls = set 2)(24). They reported two SNPs (rs1310182 and rs3789604) on a common haplotype that were associated with RA independently of rs2476601/Trp 620 (rs1310182 P = 0.002 and 0.052 for sample sets 1 and 2, respectively and for rs3789604 P = 0.002 and 0.014 for sample sets 1 and 2, respectively). In another RA study, Steer et al.(22) genotyped 45 SNPs from the PTPN22 region using Affymetrix and Illumina GWA technology on pools of 250 RA cases and 250 controls. They reported a SNP (rs1343125) in the gene MAGI3 that provided some evidence for an association independent of rs2476601/Trp 620 (P = 0.03). For type 1 diabetes, two studies proposed that there is evidence for allelic heterogeneity. Onengut-Gumuscu et al. (23) resequenced the coding regions in 94 type 1 diabetes cases and genotyped eleven SNPs in 374 type 1 diabetes families. They identified a rare nsSNP K750N, which generates a premature stop codon, and presented some evidence of association with type 1 diabetes (P = 0.026, MAF = 0.006). An Asian population study (25) did not detect the rs2476601/Arg620Trp variant in 1,690 Japanese or 180 Korean subjects, but found a promoter SNP -1123G/C (rs2488457) to be associated with type 1 diabetes (P = 0.0105;OR = 1.41, 95% CI = 1.09-1.82). They also genotyped this SNP in 95 families from the Diabetes UK Warren 1 Repository, and found the associations to be the same for -1123G/C (rs2488457) and rs2476601/Trp 620 (P = 0.019; RR = 1.46, 95% CI = 1.06 -2.01; and P = 0.046; RR = 1.46, 95% CI = 1.01 -2.13, respectively) (25) . Furthermore, a Norwegian RA study of 861 cases and 559 controls (26) found they could not distinguish between -1123G/C (rs2488457) and rs2476601/Trp 620 , due to linkage disequilibrium ( LD).
Recently, Chelala et al. (27) genotyped the RA-associated SNP rs3789604, which marks a haplotype that may be associated with RA independently of rs2476601/Trp 620 , and the Japanese associated SNP rs2488547, but failed to find evidence of an independent association with type 1 diabetes in 528 French, Danish and U.S.A. multiplex families (27) . Heward et al.(28) ) and a protective haplotype (haplotype 3, P = 3.7 x 10 -5 ) (28) . Dissection of the association of these haplotypes revealed that rs2476601/Trp 620 was responsible for the predisposing effect observed with haplotype 2, but could not explain the apparent protective effect obtained for haplotype 3 (28) .
Two previous studies have explored heterogeneity in the disease-predisposing effect of rs2476601/Trp 620 with regard to HLA class II genotype. Hermann et al. (29) observed the effect of rs2476601/Trp 620 was more pronounced in subjects with non-DR4-DQ8/low risk HLA genotypes, P = 0.0004, from a dataset of 546 cases, 538 controls and 245 nuclear families from Finland; mean age at diagnosis of cases = 8.2 years ± 4.1 years. They also reported some evidence that boys carrying the rs2476601 Trp 620 allele were at higher risk of disease than girls, P = 0.021 (29) . In Steck et al. (30) it was observed that after stratification by high-risk HLA-DR3/4 genotype, the effect of rs2476601/Trp 620 was greater in the non-DR3/4 subgroup (OR = 2.07, 95% CI = 1.54-2.79; P <0.0001) compared to DR3/4 positive cases (OR = 1.44, 95% CI = 0.85-2.45; P = 0.18), using 690 non-Hispanic white cases (NHWs) and 515 NHW controls (mean age at diagnosis of cases = 11.2 years, range 0.3-54 years).
In the current study, we assessed as comprehensively as possible given current knowledge of the polymorphism content of the region, from our resequencing and public databases, whether rs2476601/Trp 620 is the sole type 1 diabetes susceptibility variant in PTPN22, and then whether there was any evidence for additional disease risk alleles or haplotypes in the entire 400 kb LD block containing PTPN22 and at least six other Figure 1) . Research. Most affected individuals were <16 years of age at the time of collection (mean age at diagnosis = 7.5 years, range 0.5 -16 years) and all resided in Great Britain. The control samples were obtained from the British 1958 Birth Cohort (B58C), an ongoing study of all people born in Great Britain during one week in 1958. All cases and controls were of self-reported white ethnicity. The relevant research ethics committees approved the study, and written informed consent was obtained from the participants, or their parents/guardian for those too young to consent. A total of 2,400 controls and 2,800 cases had been genotyped as part of the nsSNP GWA study (31) , and 3,000 controls and 2,000 cases were genotyped as part of the Wellcome Trust Case-Control Consortium (WTCCC) GWA study(12), with 1,100 controls and 1,700 cases being common to both studies. For Taqman fine-mapping genotyping, a maximum of 7,200 controls and 7,600 cases were used encompassing all the samples from both GWA studies. PTPN22 sequencing. Polymorphisms in PTPN22 were identified by resequencing 32 Centre d'Etude du Polymorphisme Humain (CEPH) DNA samples (from Utah residents with northern and western European ancestry) in common with HapMap www.hapmap.org (32). The sequencing reactions were performed using Applied Biosystems' BigDye (version 3.1) chemistry and the sequences resolved using an ABI 3700 Genetic Analyzer. Analyses of the sequence traces were performed using the Staden package. All 14 newly discovered SNPs have been submitted to dbSNP. Genotyping methods. Information for the PTPN22 region was taken from: the WTCCC study, which used the GeneChip 500K Mapping Array Set (Affymetrix chip) (12), with Molecular Inversion Probe (MIP) technology (Affymetrix) as part of our nsSNP GWA study (31; 33) and TaqMan (Applied Biosystems) genotyping which was carried out in accordance with the manufacturers' protocols. All genotyping data were scored blind to case-control status; Taqman genotyping was double scored by a second operator to minimise error. We used the clustering method developed by Plagnol et al (34) to address bias due to differential misclassification in genotyping in large-scale association studies, to call genotypes of SNPs incorporated in our nsSNP GWA study (13) Initially, despite almost perfect LD (r 2 = 0.994 in controls) between rs2476601 and rs6679677, we found that we could apparently differentiate between the effects of the two SNPs in stepwise logistic regression analyses. The P-value for adding rs2476601 to rs6679677 was 0.010 and in the reverse regression analysis, adding rs6679677 to rs2476601, P = 0.497, suggesting that rs2476601 was sufficient to model the association. This result was unexpected given the almost perfect LD and consequently, when we then merged data from three TaqMan genotyping assays of duplicate genotyping of the case-control collection, genotyped at different times for rs2476601, we identified 36 individuals who were discordant between assays. After resequencing these 36 individuals for both rs2476601 and rs6679677, we identified 15 out of the 36 individuals who had genuinely different genotypes at rs2476601 and rs6679677. The remaining 21 differences were due to random genotyping error (less than 0.5 %) and were excluded. On repeating the logistic regression analysis, as expected, no effects were observed at P <0.05. These results highlight the sensitivity of the logistic regression analysis to genotyping error and missing data.
RESEARCH DESIGN AND METHODS

Subjects
STATISTICAL ANALYSES
All statistical analyses were performed in either Stata (http://www.stata.com/) or the R environment (http://www.rproject.org/). Logistic regression models were used for all case-control association tests. We stratified the analysis by place of collection for the cases and place of birth for the controls for 12 geographical regions of England, Scotland and Wales (Southwestern, Southern, Southeastern, London, Eastern, Wales, Midlands, North Midlands, Northwestern, East and West Riding, Northern, and, Scotland) to exclude the possibility of confounding by geography with little loss of power, given how well the cases and controls were matched geographically (31) .
In the logistic regression analysis of a SNP, we performed a one-degree of freedom (1-d.f.) likelihood ratio test to determine whether a 1-d.f. multiplicative allelic effects model or a 2-d.f. genotype model (no specific mode of inheritance assumed) was more appropriate (35) . We assumed a multiplicative allelic effects model, as it was not significantly different from the genotype model. SNPs were modelled as a numerical indicator variable coded 0,1 or 2, representing the number of occurrences of the minor allele. In the forward logistic regression analysis, we started by assessing the evidence against the most significant SNP being the sole variant in the region (in other words, whether this SNP alone was sufficient to model the association). For the purposes of this analysis, we assumed the genotype (2-d.f) parameterisation for the most associated SNP (A>a) or for any additional SNP with significant independent effects on type 1 diabetes, so genotype risks of A/A and A/a were modelled relative to the a/a genotype. We then used a 1-d.f. test for adding each of the remaining SNPs to the model by assuming multiplicative allelic effects for the additional SNPs. To correct the most significant P-value
) for the addition of rs735074 in the forward logistic regression analysis for multiple testing, we performed a permutation test to estimate the probability of observing a test statistic at least as large as ∧ θ , when the null hypothesis is true (that is, when no additional SNP significantly adds to the model). We stratified by rs735074 genotype, randomly assigning case-control status within these strata, and then adding in each SNP to the model, including the most associated. After recording the largest test statistic achieved under the null hypothesis, we repeated the permutation of disease status and analyzed 300 times. The corrected P value then equals the number of times that the largest test statistic achieved under the null hypothesis is at least as large as The six SNP haplotypes were assigned to subjects (cases and controls separately) using SNPHAP (http://wwwgene.cimr.cam.ac.uk/clayton/software/) and analyzed using logistic regression models for each subject. Haplotype assignments were weighted by their posterior probabilities and, the Huber/White/Sandwich estimate of variance was used to allow for the non-independence between the possible haplotype assignments to each individual. In addition to testing the overall significance of the six SNP haplotype, we tested whether any of the SNPs alone were sufficient to model the association or, in addition to the five SNP haplotype of the remaining SNPs, are independently associated, the latter providing evidence of allelic heterogeneity. We performed this analysis for each SNP, by dropping the SNP from the six SNP haplotypes and testing whether the five SNP haplotypes were independently associated when added to the SNP. We also performed the reverse analysis, testing whether the SNP was independently associated when added to the five SNP haplotype.
Statistical interaction between loci can be tested using a case-only analysis within a regression model (15; 36-38) . The PTPN22 nsSNP, rs2476601/Arg620Trp was put in a regression model as the dependent variable, the SNP genotypes as predictor variables and geographical region included as strata. A case-only interaction was performed for age at diagnosis and sex. However, for HLA, the number of HLA class II genotypes (over 200) that exist in our collection, means there are too many parameters to estimate and, therefore, we grouped the HLA-DRB1 and HLA-DQB1 genotypes together using three different strategies. The first is a 12 group risk-based model derived using recursive partitioning: individuals are categorized into groups according to their class II genotype such that each group is as homogeneous with respect to case/control status as possible (2) . The second grouping, classifies individuals as high risk, medium risk and low risk according to the haplotype risk estimates published in Table 3 of Koeleman et al. (39) : risks greater than 1 with 95% CI's that did not overlap 1 were classed high risk; risks with 95% CI's overlapping 1 were medium risk and risks less than 1 with 95% CI's that did not overlap 1 were classed low risk (2; 39). The third method groups together individuals with HLA-DRB1*03/HLA-DRB1*04 genotypes, versus those without. Genotypes positive for HLA-DRB1*0403 and HLA-DQB1*0301 alleles were put in the nonDRB1*03/HLA-DRB1*04 group. We used a log-linear model to estimate joint effects of PTPN22 and HLA class II in the logistic regression while maintaining the efficiency of the case-only estimate of interaction terms (40) . We assumed that the HLA and rs2476601 genotypes are conditionally independent in controls given geographical region as strata. This is a fourway contingency table of disease status (D: coded 0=controls, 1=case), rs2476601 genotype (G; coded as a 3-level factor one for each genotype), HLA group (M; coded as a factor with levels for each group e.g. two levels for the DR3/4 versus non-DR3/4 grouping) and geographical region (S; coded as a 12-level factor). We fitted the model, 6 , parameterize the independent relationship between HLA group and rs2476601 genotype, within controls, allowing for strata (geographical region). Specifically, b 1 is the log odds of a particular HLA group in controls and b 5 gives this within strata. b 2 is the log odds of having rs2476601 susceptible genotype in controls and b 6 gives this within strata. A logistic model is assumed for disease risk so that b 8 and b 9 assess the HLA and HLA*PTPN22 interaction effects i.e. b 9 , gives the log odds ratio of rs2476601 for each HLA group and are reported in Table  4 .
Measures of LD, D' and r 2 , were calculated using the Haploview package (http://www.broad.mit..edu/mpg/haploview/ ), the plots were subsequently generated and displayed through T1Dbase (www.t1dbase.org) for Supplementary Figure 1 .
RESULTS
We resequenced all 21 exons of PTPN22 and 3 kb of 5´ and 3´ sequence of the gene using DNA from 32 CEPH individuals (32), identifying 33 SNPs and one indel, 14 of which were novel when compared to genome build 36. Twenty-three SNPs had a MAF > 0.05 (Supplementary Table 1 ). Twenty-four SNPs from dbSNP and 22 SNPs discovered from resequencing were incorporated into a GWA study of nsSNPs using the MIP technology (31; 33) for genotyping in up to 3,000 type 1 diabetes case and 2,400 control samples ( Figure  1) .
To assess the evidence against rs2476601/Arg620Trp being the sole causal variant in the region, we used a logistic regression analysis to test whether rs2476601/Arg620Trp alone was sufficient to model the association. We assumed no specific mode of inheritance for rs2476601/Arg620Trp and used a 1-degree of freedom test for adding each SNP to the model. We found that when the number of tests was considered, no SNP convincingly added to rs2476601/Arg620Trp in the logistic regression analysis (minimum (uncorrected) P = 0.0423 ss73688598; Table  1 ). We also performed the reverse analysis, adding rs2476601/Arg620Trp to each of the other 46 SNPs; we found that rs247660/1Arg620Trp significantly added to all the SNPs (P max = 1.57 x 10 -34
). This is consistent with rs2476601/Arg620Trp being the sole causal variant in the region.
To assess further the evidence against rs2476601/Arg620Trp being the sole causal variant in the wider PTPN22 region, we selected 111 SNPs from the 400 kb LD block containing PTPN22 and from 200 kb regions either side of the LD block, that had been genotyped in 2,000 type 1 diabetes cases and 3,000 controls as part of the WTCCC GWA study (12). We noted that although the nsSNP rs2476601/Arg620Trp was not included on the GeneChip 500K Mapping Array Set (Affymetrix chip) used for genotyping by the WTCCC GWA study, rs2476601/Arg620Trp was in perfect LD (r 2 = 1) with rs6679677, an intergenic SNP between the genes PHTF1 and RSBN1, in the 3,000 British controls; this near perfect LD has been reported by others (12; 17). We genotyped rs6679677 and rs2476601/Arg620Trp in the full case-control collection, 7,500 cases and 7,200 controls. We found that we could not distinguish between the effects of the two SNPs on type 1 diabetes (Table 2) . We found that only 15 out of 14,487 samples had discordant genotypes at both SNPs, giving an r 2 of 0.996 in cases and 0.994 in controls; we ruled out random genotyping error by resequencing these individuals and verifying their genotypes (Research Design and Methods).
From the WTCCC GWA study, 13 SNPs had P < 4.28 x 10 -8 , with rs6679677 being the most associated (P = 1.32 x 10 -23 , OR for minor allele A = 1.88 (95% CI = 1.66-2.13) (Supplementary Table 2 , Supplementary Figure 1 ). We performed a forward logistic regression analysis on these 110 WTCCC SNPs from the wider PTPN22 region to test if there was any evidence for a variant associated with type 1 diabetes independently of rs6679677. After correcting the most associated additional SNP, there was no evidence of any additional independent effects (minimum uncorrected P = 0.00854 for rs735074 located in the flanking LD block, corrected P = 0.243), including the previously associated MAGI3 SNP rs1343125 (22) (uncorrected P = 0.907), the Japanese associated SNP rs2488457 (25)(uncorrected P = 0.866) and the RA-associated SNP rs3789604(24)(uncorrected P = 0.401) ( Table 1 and Supplementary Table 2) .
We genotyped an additional five SNPs with Taqman as they were not covered by either GWA scan: two SNPs (rs1310182 and rs2488458) associated with RA from Carlton et al. (24) , the rare nsSNP (ss73688585/K750N) associated with type 1 diabetes from Onengut-Gumuscu et al. (23) , and two SNPs (rs3789608 and ss73688608) found from our resequencing. Although we found evidence for associations between type 1 diabetes and rs1310182 (P = 9.33 x 10 -13 ), rs2488458 (P = 3.46 x 10 -34
) and ss73688608 (P =1.80 x 10 -7 ), these results were not independent of rs2476601/Arg620Trp (uncorrected P = 0.840, 0.343 and 0.702, respectively). No evidence of an association was found with either rs3789608 or ss73688585/K750N (uncorrected P = 0.0615 and 0.117, respectively).
We also tested the six SNP haplotypes from the Graves' study by Heward et al. (28) (rs2488458, rs12730735, rs2476601, rs1310182, rs1217413 and rs3811021) in 3,129 cases and 3,633 controls for which we obtained complete data for all six SNPs. The haplotypes we identified correlated with the ten common haplotypes identified in the Graves' study (28) and also the previous RA study (24) (Table 3) . We found that the susceptible haplotype (haplotype 2), the only haplotype to carry the T/Trp allele of rs2476601/Arg620Trp, was associated with disease, consistent with the two previous studies (Table 3) . We did not, however, obtain any evidence for protective haplotypes in contrast to the Graves' study, in which haplotype 3 was protective (28) , and in the RA study, haplotypes 5 and 6 were protective (24) ( Table 3 ). In our study the Arg 620 protective allele-bearing haplotype 3 was slightly increased in frequency in the cases, but this is unlikely to be a true result given the multiplicity of tests (OR = 1.31, 95% CI = 1.00-1.72, P = 0.048). More importantly, we noted that the control frequency for haplotype 3 in the Graves' study is unexpectedly higher (0.062) than for the control frequency in our study (0.022) or the RA study (0.034 and 0.032) (24) , and may account for the apparent protective haplotype effect reported previously (28) (Supplementary  Table 3 ). Furthermore, in contrast to the Graves' study, but consistent with the RA study, the SNPs used in the haplotype analysis (rs2476601, rs2488458, rs12730735, rs1310182, rs1217413 and rs3811021) were all associated with type 1 diabetes. None of these SNP associations were found to be independent, as expected, of rs2476601/Arg620Trp (Table 3 ).
Finally, we tested for evidence of a statistical interaction of rs2476601/Arg620Trp with age at T1D diagnosis and sex in the case subjects, obtaining no convincing support for interaction in 7,443 cases (P = 0.106 and 0.219, respectively). We did, however, find evidence for statistical interaction with the HLA class II genotypes, for all three MHC class II groupings considered, in up to 2,459 cases (Table 4 ) with a minimum P = 1.36 x 10 -4 . Specifically, the relative risk of rs2476601/Trp 620 is higher in low-risk HLA genotypes, e.g. non-DR3/4 (RR = 2.10) than the high-risk DR3/4 (RR = 1.59).
DISCUSSION
After extensive resequencing and genotyping of the PTPN22 region we have found that we are unable to distinguish statistically between two associated SNPs, rs2476601/Trp 620 and rs6679677, located 73 kb apart. rs6679677 is located in the intergenic region between PHTF1 and RSBN1, and does not have an obvious potential functional effect, nor does it reside in a transcriptional factor binding site, CpG island or highly conserved sequence block. The TFMATRIX web tool, however, predicts the disruption of a binding site of promoter CCAAT binding factors by this SNP. The nsSNP rs2476601/Arg620Trp, changes the amino acid residue 620 from Arg to Trp in the encoded LYP protein, a well established suppressor of T cell activation (7; 41) . Recently, it has been shown that Arg620Trp is a functional residue in the Pro-rich motif in LYP that binds the SH3 domain of CSK, Trp 620 fails to bind CSK (19) . Trp 620 may, however, lead to a gain of function, more negative regulation of the immune system, such that cells in vitro were reported to be less responsive in individuals with the susceptibility allele, rather than the expected over activation due to loss of PTPN22 function, with this minor, disease-associated allotype.
We have provided evidence of statistical interaction between HLA class II genotypes and a non-MHC HLA susceptibility locus in agreement with two previous studies from Hermann et al. (29) and Steck et al. {Steck, 2006 #114 ). This interaction cannot be interpreted biologically (42) , and all that we are able to conclude from it is that despite the relative risk of PTPN22 being higher in low risk HLA genotypes, the combined risk of diabetes for individuals carrying high risk HLA and PTPN22 genotypes is higher than those carrying low risk HLA genotypes and high risk PTPN22 genotypes. The finding of a statistical interaction may indicate that a gain of power may be possible in GWA studies of non-MHC loci, if T1D cases with high-risk HLA alleles are excluded from the analysis. This hypothesis is also supported by previous observation that non-MHC loci had smaller relative risks in affected sibpairs (who are "DR3/4" rich) than in single affected sibling families, or case/control collections and that epistatic models could explain such observations (2; 43). In comparison to PTPN22, we note that for INS, there is no evidence for a statistical interaction with HLA class II genotypes, P ≥ 0.0976, for all three MHC class II groupings considered in the same sample set (not shown).
Our results support the hypothesis that rs2476601/Arg620Trp is the most likely causal variant for type 1 diabetes and that for this disease, in large sample sizes, there is no evidence for allelic heterogeneity. However, the possibility still remains that an alternative or as yet unidentified variant(s) could have a role in disease susceptibility, as it is not known how many more SNPs are in the region, since the entire LD region has not been resequenced. For example, 73 kb telomeric of rs2476601/Arg620Trp, SNP rs6679677 is in perfect LD with the PTPN22 functional candidate SNP, and genetically and statistically, therefore, is as good a positional candidate as PTPN22 rs2476601/Arg620Trp. Our failure to obtain any evidence for allelic heterogeneity or haplotype effects in type 1 diabetes for this chromosome region, suggests that for type 1 diabetes previous studies (23; 25; 26) could have been false positives especially since much smaller sample sizes were studied. We cannot comment on the validity of additional variants in RA and Graves' disease (22; 24; 28), except that any result should be replicated in additional datasets. Nevertheless, it does appear that the haplotype effect in Graves' disease (28) may be due to fluctuation in control haplotype frequencies rather than a genuine difference between case and control frequencies.
With the recent availability of next generation sequencing technologies (44) (45) (46) the essential next step in the localisation and disease association analysis of all the variation in this region of chromosome 1p13 will be made more feasible, being less labour-intensive and costly. It will not be surprising if additional variants are found that are in near perfect LD with rs2476601/Arg620Trp, as in the case for SNP rs6679677, making them genetically plausible candidates for this type 1 diabetes locus. Furthermore, it is possible that an unknown variant exists in the region that is not in complete LD with rs2476601 and is more strongly associated with type 1 diabetes. Further genetic studies, including in populations with different genetic diversity from European populations, combined with targeted functional studies will confirm unequivocally rs2476601/Arg620Trp as the sole type 1 diabetes locus in the region. Not withstanding this possibility, our results so far provide no evidence for allelic heterogeneity and support an aetiological role for the rs2476601/Trp 620 allele. 
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